215 related articles for article (PubMed ID: 37771632)
41. Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma.
Zhang B; Zhang T; Zheng Z; Lin Z; Wang Q; Zheng D; Chen Z; Ma Y
Front Oncol; 2022; 12():1020566. PubMed ID: 36713586
[TBL] [Abstract][Full Text] [Related]
42. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer.
Wen H; Qu C; Wang Z; Gao H; Liu W; Wang H; Sun H; Gu J; Yang Z; Wang X
FASEB J; 2023 Sep; 37(9):e23145. PubMed ID: 37584654
[TBL] [Abstract][Full Text] [Related]
43. Comprehensive analysis of the relationship between cuproptosis-related genes and esophageal cancer prognosis.
Xu H; Du QC; Wang XY; Zhou L; Wang J; Ma YY; Liu MY; Yu H
World J Clin Cases; 2022 Nov; 10(33):12089-12103. PubMed ID: 36483804
[TBL] [Abstract][Full Text] [Related]
44. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.
Du Y; Jiang W; Hou S; Chen Z; Zhou W
Biomed Res Int; 2023; 2023():3419401. PubMed ID: 36714025
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive analyses of cuproptosis-related gene CDKN2A on prognosis and immunologic therapy in human tumors.
Zhang D; Wang T; Zhou Y; Zhang X
Medicine (Baltimore); 2023 Apr; 102(14):e33468. PubMed ID: 37026918
[TBL] [Abstract][Full Text] [Related]
46. A risk prognostic model for patients with esophageal squamous cell carcinoma basing on cuproptosis and ferroptosis.
Li J; Liu J; Li J; Feng A; Nie Y; Yang Z; Zhang W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11647-11659. PubMed ID: 37405477
[TBL] [Abstract][Full Text] [Related]
47. Research progress on cuproptosis in cancer.
Feng Q; Huo C; Wang M; Huang H; Zheng X; Xie M
Front Pharmacol; 2024; 15():1290592. PubMed ID: 38357312
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms of cuproptosis and its relevance to distinct diseases.
Lou QM; Lai FF; Li JW; Mao KJ; Wan HT; He Y
Apoptosis; 2024 Jun; ():. PubMed ID: 38824478
[TBL] [Abstract][Full Text] [Related]
49. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
50. Exploring cuproptosis as a mechanism and potential intervention target in cardiovascular diseases.
Yang Y; Feng Q; Luan Y; Liu H; Jiao Y; Hao H; Yu B; Luan Y; Ren K
Front Pharmacol; 2023; 14():1229297. PubMed ID: 37637426
[TBL] [Abstract][Full Text] [Related]
51. A Stimulus-Responsive Ternary Heterojunction Boosting Oxidative Stress, Cuproptosis for Melanoma Therapy.
Huang Y; Chen C; Tan H; Dong S; Ren Y; Chao M; Yan H; Yan X; Jiang G; Gao F
Small; 2024 May; ():e2401147. PubMed ID: 38770990
[TBL] [Abstract][Full Text] [Related]
52. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma.
Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C
Front Genet; 2023; 14():1124439. PubMed ID: 36936439
[No Abstract] [Full Text] [Related]
53. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma.
Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX
Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711
[TBL] [Abstract][Full Text] [Related]
54. Pan-cancer profiles of the cuproptosis gene set.
Liu H
Am J Cancer Res; 2022; 12(8):4074-4081. PubMed ID: 36119826
[TBL] [Abstract][Full Text] [Related]
55. Cuproptosis-related lncRNAs predict the clinical outcome and immune characteristics of hepatocellular carcinoma.
Zhu H; Mao F; Wang K; Feng J; Cheng S
Front Genet; 2022; 13():972212. PubMed ID: 36212138
[TBL] [Abstract][Full Text] [Related]
56. A novel defined cuproptosis-related gene signature for predicting the prognosis of lung adenocarcinoma.
Zhang H; Shi Y; Yi Q; Wang C; Xia Q; Zhang Y; Jiang W; Qi J
Front Genet; 2022; 13():975185. PubMed ID: 36046242
[TBL] [Abstract][Full Text] [Related]
57. Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer.
Yang X; Deng L; Diao X; Yang S; Zou L; Yang Q; Li J; Nie J; Zhao L; Jiao B
iScience; 2023 Nov; 26(11):108218. PubMed ID: 37953954
[TBL] [Abstract][Full Text] [Related]
58. Integrated machine learning and bioinformatic analyses used to construct a copper-induced cell death-related classifier for prognosis and immunotherapeutic response of hepatocellular carcinoma patients.
Zhao S; Chen S; Liu W; Wei S; Wu X; Cui D; Jiang L; Chen S; Wang J
Front Pharmacol; 2023; 14():1188725. PubMed ID: 37266152
[No Abstract] [Full Text] [Related]
59. An Intelligent Cell-Derived Nanorobot Bridges Synergistic Crosstalk Between Sonodynamic Therapy and Cuproptosis to Promote Cancer Treatment.
Chen K; Zhou A; Zhou X; Liu Y; Xu Y; Ning X
Nano Lett; 2023 Apr; 23(7):3038-3047. PubMed ID: 36951267
[TBL] [Abstract][Full Text] [Related]
60. Identification of key cuproptosis-related genes and their targets in patients with IgAN.
Lin H; Wu D; Xiao J
BMC Nephrol; 2022 Nov; 23(1):354. PubMed ID: 36329405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
